Insmed (INSM) reported preliminary 2024 revenue results for its drug Arikayce and issued 2025 revenue guidance. Read more ...

NuScale's regulatory approval for SMRs in the U.S. gives it a unique market position, with a major project to go live in 2029 ...

“We see more good than bad happening in 2025 and believe this will cause Softline’s’ valuation gap vs the S&P 500 to narrow, ...

US job growth surged in December, surpassing expectations. The services sector drove gains, but wage growth slightly slowed.

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Starbucks' premium valuation is harder to justify amid declining performance. Find out why SBUX stock may face more downside, ...

As the private credit market rapidly evolves, we believe investors should consider a more flexible and specialized allocation ...

Microsoft’s focus on long-term AI success explains recent stock behavior. See why MSFT stock, with recent reallocations, is ...

Washington Trust Bancorp has seen significant growth, but now faces mixed financial performance. Click here to find out why I ...

BioCryst ( NASDAQ: BCRX) released its preliminary 2024 revenue results, along with guidance for 2025. The company said it ...

The Hershey Company is a strong hold, but Mondelez offers growth potential. See why HSY and MDLZ stocks could offer better ...

Solana's advancements in scalability, security, and developer growth make it a strong long-term hold, despite potential short ...